2024
Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma
Witzig T, Sokol L, Kim W, de la Cruz Vicente F, Martín García-Sancho A, Advani R, Roncero Vidal J, de Oña Navarrete R, Marin-Niebla A, Rodriguez Izquierdo A, Terol M, Domingo-Domenech E, Saunders A, Bendris N, Mackey J, Leoni M, Foss F. Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma. Blood Advances 2024, 8: 4581-4592. PMID: 38991123, DOI: 10.1182/bloodadvances.2024012806.Peer-Reviewed Original ResearchRelapsed/refractory peripheral T-cell lymphomaAngioimmunoblastic T-cell lymphomaPeripheral T-cell lymphomaT-cell lymphomaProgression-free survivalDuration of responseAdverse eventsAngioimmunoblastic T-cell lymphoma patientsMedian duration of responseMedian progression-free survivalSafety of tipifarnibHematologic adverse eventsMedian overall survivalTreatment-related deathsBiomarkers of responsePhase 2 trialSixty-five patientsFarnesyltransferase inhibitor tipifarnibNon-responder groupTumor mutational profileSingle-arm trialPTCL-NOSOpen-labelOverall survivalPrimary endpointClinical and Histologic Variants of CD8+ Cutaneous T-Cell Lymphomas
Swallow M, Micevic G, Zhou A, Carlson K, Foss F, Girardi M. Clinical and Histologic Variants of CD8+ Cutaneous T-Cell Lymphomas. Cancers 2024, 16: 3087. PMID: 39272944, PMCID: PMC11394026, DOI: 10.3390/cancers16173087.Peer-Reviewed Original ResearchT-cell lymphomaPrimary cutaneous gamma/delta T-cell lymphomaSubcutaneous panniculitis-like T-cell lymphomaLymphoproliferative disordersMycosis fungoidesCD8+ cutaneous T-cell lymphomasCutaneous gamma/delta T-cell lymphomaPanniculitis-like T-cell lymphomaGamma/delta T-cell lymphomaCytotoxic T-cell lymphomaT-cell lymphoproliferative disorderAbnormal T-cell populationCutaneous T-cell lymphomaCytotoxic molecule expressionT cell populationsIndicator of prognosisAppropriate treatment planCD8-positiveAggressive entityLymphomatoid papulosisHistological variantsHistopathological differentiationTreatment algorithmCD8Clinical manifestationsValemetostat Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas: Primary Results From a Phase 1 Trial
Maruyama D, Porcu P, Tobinai K, Allen P, Ishitsuka K, Tsukasaki K, Kusumoto S, Narita T, Foss F, Yamauchi N, Yuda J, Morishima S, Imaizumi Y, Izutsu K, Feldman T, Kawamata T, Kakurai Y, Yamauchi H, Biserna N, Inoue A, Tachibana M, Hizukuri Y, Horwitz S, Jacobsen E. Valemetostat Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas: Primary Results From a Phase 1 Trial. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s229. DOI: 10.1016/s2152-2650(24)00908-x.Peer-Reviewed Original ResearchTCL-391 Valemetostat Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas: Primary Results From a Phase 1 Trial
Maruyama D, Porcu P, Tobinai K, Allen P, Ishitsuka K, Tsukasaki K, Kusumoto S, Narita T, Foss F, Yamauchi N, Yuda J, Morishima S, Imaizumi Y, Izutsu K, Feldman T, Kawamata T, Kakurai Y, Yamauchi H, Biserna N, Maruyama A, Tachibana M, Hizukuri Y, Horwitz S, Jacobsen E. TCL-391 Valemetostat Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas: Primary Results From a Phase 1 Trial. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s523-s524. DOI: 10.1016/s2152-2650(24)01617-3.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsB-NHLR/R NHLPartial responseEZH2 mutationsAdverse eventsMedian duration of responseRecommended phase 2 doseRelapsed/refractory non-Hodgkin lymphomaTreatment-related adverse eventsPhase 2 doseR/R follicular lymphomaNon-Hodgkin's lymphomaDuration of responseMaximum tolerated doseDecreased platelet countPhase 1 trialYears of ageFollicular lymphomaTolerated doseDose reductionOpen-labelMedian durationEfficacy analysisMedian age572 Development of immunotherapies targeting TCR-Vβ2 for treatment of cutaneous T cell lymphoma
Ren J, Liao X, Lewis J, Li D, Chang J, Swallow M, Lee J, Qu R, Carlson K, Foss F, Girardi M. 572 Development of immunotherapies targeting TCR-Vβ2 for treatment of cutaneous T cell lymphoma. Journal Of Investigative Dermatology 2024, 144: s100. DOI: 10.1016/j.jid.2024.06.588.Peer-Reviewed Original ResearchCosts of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas
Di M, Potnis K, Long J, Isufi I, Foss F, Seropian S, Gross C, Huntington S. Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas. JNCI Cancer Spectrum 2024, 8: pkae059. PMID: 39115391, PMCID: PMC11340641, DOI: 10.1093/jncics/pkae059.Peer-Reviewed Original ResearchChimeric antigen receptor T-cell therapyB-cell lymphomaRelapsed/refractory B-cell lymphomaT-cell therapyCAR-T administrationCAR-T productsMedian total costCommercially insured patientsReal-world costsMedian costOut-of-pocket copaymentsCost of careLymphomaMonthly costTherapyPatientsProduct acquisitionFinancial outcomesHigher upfront costChart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019
Girardi M, Carlson K, Huang X, Corman S, Edmundson P, Schmier J, Kale H, Raina R, Foss F. Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019. Journal Of Dermatological Treatment 2024, 35: 2360568. PMID: 38852942, DOI: 10.1080/09546634.2024.2360568.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaCutaneous T-cell lymphoma patientsExtracorporeal photopheresisResponse rateClinical outcomesMonths of ECP treatmentMedian time to responseReal-world treatment patternsECP initiationLymph node involvementStage IV diseaseAdvanced-stage diseaseT-cell lymphomaTime to responseEffective treatment optionPercentage of patientsChart review studyIV diseaseSezary syndromeNode involvementConcomitant therapySystemic therapyMedian ageMycosis fungoidesChart reviewAssociations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM).
Theprungsirikul P, Yu M, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM). Journal Of Clinical Oncology 2024, 42: 7549-7549. DOI: 10.1200/jco.2024.42.16_suppl.7549.Peer-Reviewed Original ResearchChimeric antigen receptor T cellsRelapsed/refractory multiple myelomaT cell fitnessHigh-risk cytogeneticsCytokine release syndromeNon-respondersExtramedullary diseaseT cellsPeripheral blood prior to treatmentInternational Myeloma Working Group criteriaNR groupBlood prior to treatmentBispecific T-cell engagerMedian follow-up timeMedian prior linesT-cell therapyPost-treatment follow-upT-cell engagersT cell influxT-cell %Working Group criteriaYale Cancer CenterMann-Whitney U testResponse to disease progressionIdecabtagene vicleucelAllogeneic transplantation and cellular therapies in cutaneous T-cell lymphoma
Goyal A, Foss F. Allogeneic transplantation and cellular therapies in cutaneous T-cell lymphoma. Expert Review Of Anticancer Therapy 2024, 24: 41-58. PMID: 38224371, DOI: 10.1080/14737140.2024.2305356.Peer-Reviewed Original ResearchConceptsDonor lymphocyte infusionTotal body irradiationT-cell lymphomaCAR-T cell therapyCutaneous T-cell lymphomaT-cell therapySezary syndromeAllo-HSCTT cellsLymphocyte infusionCAR-TMycosis fungoidesAllogeneic hematopoietic stem cell transplantationCAR-T cell persistenceReduced-intensity conditioning regimensHematopoietic stem cell transplantationAdvanced stage MFTemporary disease controlTreatment of MF/SSCAR-T therapyInduce complete remissionCurative treatment optionStem cell transplantationNonmalignant T cellsTime of transplantationGeneration and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy
Ren J, Liao X, Lewis J, Chang J, Qu R, Carlson K, Foss F, Girardi M. Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy. Nature Communications 2024, 15: 519. PMID: 38225288, PMCID: PMC10789731, DOI: 10.1038/s41467-024-44786-2.Peer-Reviewed Original ResearchConceptsAntibody-dependent cellular cytotoxicityDonor T cellsT cellsAdeno-associated virus transductionHealthy donor T cellsHost-versus-graft reactivityEnhanced antibody-dependent cellular cytotoxicityCAR-T cellsGraft-versus-hostT cell killingT-cell malignanciesMalignant T cellsNormal T-cellT cell receptorOff-target toxicityPre-existing immunoreactivityCAR-TDisease relapseCellular cytotoxicityVirus transductionCurrent treatmentPersister killingFc engineeringB2MIn vivo
2023
Novel Causal Inference Method Estimates Treatment Effects of Contemporary Drugs in a Global Cohort of Patients with Relapsed and Refractory Mature T-Cell and NK-Cell Neoplasms
Koh M, Boussi L, Han J, Peng L, Sorial M, Eche-Ugwu I, Miranda E, Chiattone C, Stuver R, Horwitz S, Turizo M, McCabe S, Merrill M, Jacobsen E, Kim J, Kim Y, Cho J, Eipe T, Shet T, Jain H, Sengar M, Singh S, Gabler J, Koh M, Van Der Weyden C, Prince M, Hamouche R, Muradashvili T, Foss F, Gentilini M, Casadei B, Zinzani P, Okatani T, Yoshida N, Yoon S, Kim W, Panchoo G, Mohamed Z, Verburgh E, Alturas J, Al Mansour M, Ford J, Manni M, Federico M, O'Connor O, Cabrera M, Shen C, Marchi E, Shah D, Jain S. Novel Causal Inference Method Estimates Treatment Effects of Contemporary Drugs in a Global Cohort of Patients with Relapsed and Refractory Mature T-Cell and NK-Cell Neoplasms. Blood 2023, 142: 1703. DOI: 10.1182/blood-2023-185881.Peer-Reviewed Original ResearchSuperior overall survivalCytotoxic chemotherapyOverall survivalNK-cell neoplasmsBrentuximab vedotinPTCL-NOSMultivariate CoxSingle agentALK- ALCLSmall molecule inhibitorsComparable OSGlobal cohortLargest global cohortClinical trialsT cellsConcordance indexMultivariate Cox regression modelSecond-line therapyPrimary refractory patientsIndependent prognostic effectCox regression modelMolecule inhibitorsReal-world evidenceEpigenetic modifiersMature T cellsValemetostat for Relapsed or Refractory Peripheral T-Cell Lymphomas: Primary Results from a Phase 1 Trial
Jacobsen E, Maruyama D, Porcu P, Tobinai K, Allen P, Ishitsuka K, Tsukasaki K, Kusumoto S, Foss F, Yamauchi N, Morishima S, Imaizumi Y, Izutsu K, Feldman T, Kawamata T, Kakurai Y, Yamauchi H, Biserna N, Inoue A, Tsutsumi S, Horwitz S. Valemetostat for Relapsed or Refractory Peripheral T-Cell Lymphomas: Primary Results from a Phase 1 Trial. Blood 2023, 142: 303. DOI: 10.1182/blood-2023-172512.Peer-Reviewed Original ResearchPeripheral T-cell lymphomaAdult T-cell leukemia/lymphomaT-cell non-Hodgkin lymphomaObjective response rateDuration of responseProgression-free survivalT-cell lymphomaMedian DORATLL groupPTCL groupData cutoffAdverse eventsClinical activityResponse rateRefractory peripheral T-cell lymphomaMedian progression-free survivalAngioimmunoblastic T-cell lymphomaT-cell leukemia/lymphomaDose-expansion cohortsDose-expansion phaseMedian prior therapiesPreliminary efficacy assessmentComplete response rateDose-escalation phasePhase 2 trialImpact of Therapy Sequence on Survival Outcomes Among Patients with Relapsed or Refractory Mature T and NK Cell Neoplasms: A Global Retrospective Cohort Study
Sorial M, Koh M, Boussi L, Han J, Peng L, Eche-Ugwu I, Duan R, Lei M, Miranda E, Chiattone C, Stuver R, Horwitz S, Turizo M, McCabe S, Merrill M, Jacobsen E, Kim J, Kim Y, Cho J, Jain H, Sengar M, Eipe T, Shet T, Singh S, Lou U, Raghib H, Gabler J, Koh M, Van Der Weyden C, Prince M, Hamouche R, Muradashvili T, Foss F, Gentilini M, Casadei B, Zinzani P, Okatani T, Yoshida N, Yoon S, Kim W, Panchoo G, Mohamed Z, Verburgh E, Alturas J, Al Mansour M, Ford J, Manni M, Federico M, O'Connor O, Cabrera M, Marchi E, Shen C, Shah D, Jain S. Impact of Therapy Sequence on Survival Outcomes Among Patients with Relapsed or Refractory Mature T and NK Cell Neoplasms: A Global Retrospective Cohort Study. Blood 2023, 142: 3080. DOI: 10.1182/blood-2023-182341.Peer-Reviewed Original ResearchNK-cell neoplasmsTherapy sequenceCohort studyMost patientsSurvival outcomesPatient cohortCox modelAnaplastic large cell lymphomaFirst lineAllogeneic hematopoietic transplantOptimal therapy sequencePTCL-NOS patientsRetrospective cohort studyKaplan-Meier curvesLarge cell lymphomaEpigenetic modifiersImmunomodulatory imide drugsPI3K inhibitorsAntibody-drug conjugatesAllogeneic HSCTCommon histologyPlanned subgroupPrimary refractoryAutologous HSCTHazard ratioAllogeneic stem cell transplant for treatment of mycosis fungoides and Sezary syndrome: a systematic review and meta-analysis
Goyal A, O’Leary D, Foss F. Allogeneic stem cell transplant for treatment of mycosis fungoides and Sezary syndrome: a systematic review and meta-analysis. Bone Marrow Transplantation 2023, 59: 41-51. PMID: 37853164, DOI: 10.1038/s41409-023-02122-0.Peer-Reviewed Original ResearchConceptsGraft-versus-host diseaseReduced-intensity conditioningDonor lymphocyte infusionAllo-HSCTStem cell transplantationMyeloablative conditioningSezary syndromeOverall survivalMycosis fungoidesCell transplantationRates of graft-versus-host diseaseTreated with donor lymphocyte infusionsChronic graft-versus-host diseaseAllogeneic hematopoietic stem cell transplantationMeta-analysisAdvanced-stage mycosis fungoidesAssociated with superior OSGraft-versus-lymphoma effectOutcomes of allo-HSCTAllogeneic stem cell transplantationHematopoietic stem cell transplantationTreatment of mycosis fungoidesGraft-versus-lymphomaNon-relapse mortalityProgression-free survivalCost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma
Potnis K, Di M, Isufi I, Gowda L, Seropian S, Foss F, Forman H, Huntington S. Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma. Blood Advances 2023, 7: 801-810. PMID: 36342852, PMCID: PMC10011202, DOI: 10.1182/bloodadvances.2022008097.Peer-Reviewed Original ResearchConceptsCAR T-cell therapyT-cell therapyQuality-adjusted life yearsIncremental cost-effectiveness ratioCAR T cellsChimeric antigen receptor T-cell therapySOC therapyFollicular lymphomaT cellsLife yearsR FLRefractory follicular lymphomaT cell strategiesThird-line settingLines of therapyIncremental clinical benefitUS payer perspectiveCost-effectiveness ratioTherapy remissionUnselected patientsCare therapyClinical benefitClinical trialsTreatment strategiesPayer perspectiveIntegrated transcriptome and trajectory analysis of cutaneous T-cell lymphoma identifies putative precancer populations
Ren J, Qu R, Rahman N, Lewis J, King A, Liao X, Mirza F, Carlson K, Huang Y, Gigante S, Evans B, Rajendran B, Xu S, Wang G, Foss F, Damsky W, Kluger Y, Krishnaswamy S, Girardi M. Integrated transcriptome and trajectory analysis of cutaneous T-cell lymphoma identifies putative precancer populations. Blood Advances 2023, 7: 445-457. PMID: 35947128, PMCID: PMC9979716, DOI: 10.1182/bloodadvances.2022008168.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaMalignant CTCL cellsDiverse transcriptomic profilesT cellsSingle-cell RNACTCL cellsDevelopment of CTCLIntegrated transcriptomeT-cell receptor sequencingT cell exhaustion phenotypeCommon antigenic stimulusPeripheral blood CD4Transcriptomic profilesGene expressionT-cell lymphomaIntegrative analysisPotential therapeutic targetProliferation advantageLimited diversityBlood CD4Blood involvementMutation levelsExhaustion phenotypeWorse prognosisAntigenic stimulus
2022
Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion
Hodak E, Geskin L, Guenova E, Ortiz-Romero P, Willemze R, Zheng J, Cowan R, Foss F, Mangas C, Querfeld C. Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion. American Journal Of Clinical Dermatology 2022, 24: 5-14. PMID: 36399227, PMCID: PMC9673193, DOI: 10.1007/s40257-022-00732-w.Peer-Reviewed Original ResearchConceptsMycosis fungoidesDiagnostic delayPrimary cutaneous T-cell lymphomaCutaneous T-cell lymphomaEarly mycosis fungoidesT-cell lymphomaHeterogeneous clinical presentationInitial clinical appearanceInternational expert panelDermatopathological findingsClinical presentationClinical appearanceMF lesionsClinical signsDifferential diagnosisMF diagnosisCorrect diagnosisUnmet needExpert panel discussionDiagnosisExpert panelFungoidesComplex histologyCliniciansDermatologistsImpact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR)
Mirza A, Hosing C, Foss F, Kim S, Moskop A, Oloyede T, Ahmed S, Hematti P, Turtle C, Pasquini M, Gowda L. Impact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR). Blood 2022, 140: 4633-4635. DOI: 10.1182/blood-2022-163750.Peer-Reviewed Original ResearchAge, Albumin, and LDH Predict Outcome of Patients with Limited Stage Peripheral T Cell Lymphoma: A Prognostic Model Developed on 244 Cases Enrolled in the T Cell Project 1 By the International T Cell Project Network
Hapgood G, Civallero M, Stepanishyna Y, Vose J, Cabrera M, Advani R, Pileri S, Manni M, Horwitz S, Foss F, Hitz F, Radford J, Dlouhy I, Chiattone C, Kim W, Skrypets T, Nagler A, Trotman J, Luminari S, Federico M. Age, Albumin, and LDH Predict Outcome of Patients with Limited Stage Peripheral T Cell Lymphoma: A Prognostic Model Developed on 244 Cases Enrolled in the T Cell Project 1 By the International T Cell Project Network. Blood 2022, 140: 1476-1478. DOI: 10.1182/blood-2022-158883.Peer-Reviewed Original ResearchIncorporation of Machine Learning Tools to Predict Global Outcomes for Patients with Relapsed and Refractory Peripheral T and NK/T-Cell Lymphomas in the Contemporary Era
Boussi L, Koh M, Han X, Peng L, Koh M, Eche I, Ford J, Singh S, Miranda E, Chiattone C, Van Der Weyden C, Prince H, Foss F, Yoon S, Kim W, Panchoo G, Verburgh E, Alturas J, Al-mansour M, Manni M, Federico M, Cabrera M, Casadei B, Zinzani P, Yoshida N, Okatani T, Merrill M, Jacobsen E, O'Connor O, Marchi E, Jain S. Incorporation of Machine Learning Tools to Predict Global Outcomes for Patients with Relapsed and Refractory Peripheral T and NK/T-Cell Lymphomas in the Contemporary Era. Blood 2022, 140: 10976-10978. DOI: 10.1182/blood-2022-162944.Peer-Reviewed Original Research